

# APPLICATIONS

## Comparison of Polymeric and Silica-Based Columns for Oligonucleotide Analysis by Ion-Pair Reversed Phase

Ivan Lebedev, Brian Rivera  
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501, USA

### Overview

Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry. However, characterization of oligos, specifically by ion-pair reversed phase liquid chromatography (IP-RPLC), can be quite challenging. Oligos are manufactured by solid phase synthesis, where nucleotides are added in a step-wise manner. As such, process-related impurities such as n-1 and n+1 must be characterized. Further complicating methods are common mobile phase additives such as perfluorinated alcohols (HFIP) and an alkylamine ion-pair that facilitate the hydrophobic interaction of the negatively charged oligo. These mobile phase conditions combined with high temperature are often necessary to ensure good peak shapes but result in very harsh conditions that can encourage silica dissolution.

As such, the LC particle is an important consideration for column selection. The particle must be stable at neutral pH when run at moderately high temperature. It might then seem appropriate to run a polymer-based particle such as a polystyrene divinylbenzene to ensure method robustness and column stability. However, polymer-based particles typically do not have the efficiency necessary to separate the closely eluting impurities associated to oligos. Alternatively, superficially porous (core-shell) particles can be used to improve efficiency and resolution. Here, we investigate the chromatographic performance between two PS-DVB particles and the bioZen™ 2.6 µm Oligo column, which uses a pH stable organo-silica superficially porous particle packed in bio-inert hardware.

In comparing the 2.6 µm bioZen Oligo to a 5 µm PS-DVB of similar dimensions in the separation of a 2'-MOE Gapmer, there is a marked difference in chromatographic performance, with the 2.6 µm particle giving superior peak height (**Figure 1**). As such, the increase in chromatographic efficiency offered by the bioZen Oligo improves the separation of different process related impurities. This also may be due to the functionality of the C18 stationary phase that is bonded to the superficially porous particle, which has a better methylene selectivity. A similar performance for an RNA phosphorothioate is also observed, as seen in **Figure 2**. Notably, many short mer failure sequences are not detected using the 5 µm PS-DVB particle platform.


In comparing separation of a 5'-Amino C12 oligonucleotide on the 2.6 µm against a 4 µm PS-DVB column of similar dimensions (**Figure 3**), the superficially porous core-shell particle shows a slightly improved peak height and improved separation. A similar profile is observed with the BNA oligo (**Figure 4**), though the superficially porous particle yields slightly more peak areas and improved recoveries for some earlier eluting impurities. This improved recovery might be attributed to the bio-inert hardware of the bioZen Oligo, which tends to improve recovery and peak shape for oligos, especially using moderately high HFIP concentrations.

In summary, when selecting a particle for oligo analysis although a PS-DVB particle might seem like an appropriate choice, one may be making concessions for peak shape and efficiency, which might directly effect method sensitivity. Additionally, separation may not be optimal which can impact impurity analysis and characterization. The bioZen Oligo however, affords scientists a versatile combination of performance gains and robustness, along with improved recovery from bio-inert hardware.


### LC Conditions

- Columns:** bioZen 2.6 µm Oligo ([00B-4790-AN](#))  
5 µm PS-DVB  
4 µm PS-DVB
- Dimension:** 50 x 2.1 mm
- Mobile Phase:** Figures 1, 2:  
A: 12.5 mM HFIP, 0.5 mM Hexylamine in Water  
B: 12.5 mM HFIP, 0.5 mM Hexylamine in Methanol  
Figures 3, 4:  
A: 100 mM HFIP, 4 mM TEA in Water  
B: 100 mM HFIP, 4 mM TEA in Methanol
- Gradient:** 5-75 % B in 14 minutes (Figures 1,2)  
5-30 % B in 14 minutes (Figures 3,4)
- Flow Rate:** 0.3 mL/min
- Injection:** 2 µL (1 µg/mL)
- Temperature:** 65 °C (Figure 1,2)  
45 °C (Figure 3,4)
- Detection:** UV @ 260 nm
- Sample:** As indicated


**Figure 1. Comparison of Impurity Profile, 2'-MOE Gapmer**




**Figure 2. Comparison of Impurity Profile, RNA Phosphorothioate**



**Figure 3. Comparison of Impurity Profile, 5'-Amino C12 Oligonucleotide**



**Figure 4. Comparison of Impurity Profile, BNA**



# APPLICATIONS

## Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on [www.phenomenex.com](http://www.phenomenex.com), but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal [www.phenomenex.com/ChatNow](http://www.phenomenex.com/ChatNow).

### Australia

t: +61 (0)2-9428-6444  
auiinfo@phenomenex.com

### Austria

t: +43 (0)1-319-1301  
anfrage@phenomenex.com

### Belgium

t: +32 (0)2 503 4015 (French)  
t: +32 (0)2 511 8666 (Dutch)  
beinfo@phenomenex.com

### Canada

t: +1 (800) 543-3681  
info@phenomenex.com

### China

t: +86 400-606-8099  
cninfo@phenomenex.com

### Denmark

t: +45 4824 8048  
nordicinfo@phenomenex.com

### Finland

t: +358 (0)9 4789 0063  
nordicinfo@phenomenex.com

### France

t: +33 (0)1 30 09 21 10  
franceinfo@phenomenex.com

### Germany

t: +49 (0)6021-58830-0  
anfrage@phenomenex.com

### India

t: +91 (0)40-3012 2400  
indiainfo@phenomenex.com

### Ireland

t: +353 (0)1 247 5405  
eireinfo@phenomenex.com

### Italy

t: +39 051 6327511  
italiainfo@phenomenex.com

### Luxembourg

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

### Mexico

t: 01-800-844-5226  
tecnicomx@phenomenex.com

### The Netherlands

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

### New Zealand

t: +64 (0)9-4780951  
nzinfo@phenomenex.com

### Norway

t: +47 810 02 005  
nordicinfo@phenomenex.com

### Poland

t: +48 (12) 881 0121  
pl-info@phenomenex.com

### Portugal

t: +351 221 450 488  
ptinfo@phenomenex.com

### Singapore

t: +65 800-852-3944  
sginfo@phenomenex.com

### Spain

t: +34 91-413-8613  
espinfo@phenomenex.com

### Sweden

t: +46 (0)8 611 6950  
nordicinfo@phenomenex.com

### Switzerland

t: +41 (0)61 692 20 20  
swissinfo@phenomenex.com

### United Kingdom

t: +44 (0)1625-501367  
ukinfo@phenomenex.com

### USA

t: +1 (310) 212-0555  
info@phenomenex.com

### ☎ All other countries/regions Corporate Office USA

t: +1 (310) 212-0555  
info@phenomenex.com

## [www.phenomenex.com](http://www.phenomenex.com)

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at [international@phenomenex.com](mailto:international@phenomenex.com)

#### Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at [www.phenomenex.com/TermsAndConditions](http://www.phenomenex.com/TermsAndConditions).

#### Trademarks

bioZen is a trademark of Phenomenex.

Comparison do not represented all applications.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2020 Phenomenex, Inc. All rights reserved.